FMC Corporation reports Q1 2026 results today with an unusual setup: a 4% drop on the day before earnings, yet a short base that has collapsed over the past week.
The short-side story has shifted sharply. Short interest fell 12% over the past week — from roughly 14.8 million shares to 12.9 million — bringing it to 10.4% of the free float, the lowest level in six weeks. That follows an even larger 17% decline over the past month. The move suggests shorts have been actively covering rather than piling on ahead of the print. At the same time, availability is tight at just under 22% — meaning for every share already borrowed, only about one-fifth more remains in the lending pool. Cost to borrow is a modest 0.47%, down roughly 10% on the week, so the lending market is not pricing in squeeze pressure. The picture is one of a crowded-then-evacuated short position, not a fresh build.
Options traders are not positioned defensively. The put/call ratio is 0.46, slightly below its 20-day average of 0.48 and a long way from the 52-week high of 0.95. The z-score of -0.65 confirms a mild lean toward calls relative to recent norms. That sits in contrast to the stock's 4% fall on Wednesday and a 7% slide over the past month to $14.65. Whatever the options market was pricing, it was not a rush for protection.
Analysts have been notably constructive in the weeks leading up to today's call. Goldman Sachs raised its target to $21 from $17 while keeping its Buy rating in mid-April. Wells Fargo and UBS both lifted targets to $17, and RBC raised to $16, all in the past two weeks. None upgraded their ratings outright, but the direction of travel is clear: the Street moved higher on targets just ahead of earnings. The consensus mean target is $17.58 against a current price of $14.65, implying just over 14% upside. The EV/EBITDA multiple is 7.8x, down slightly on the week, while the PE of 7.95x has compressed nearly 1 point over the past month — a cheap-looking stock by historical multiples, though the EPS surprise factor score sits at just the 1st percentile, a sign the company has a history of missing estimates.
The bull case centres on a second-half volume recovery, particularly in Latin America, with management targeting roughly $600 million in H2 EBITDA. The bear case is harder to dismiss: a 9% year-over-year price decline in Q1, exacerbated by Brazilian competition, and below-consensus Q2 guidance that rattled investors after the last print. The previous two earnings events moved the stock sharply lower — down 5.9% after the April 2026 pre-release and down 13.1% the day following the February 2026 report. That pattern of heavy post-earnings selling is the live risk hanging over today's announcement.
Insider activity adds a faint contrarian signal. Director Michael Barry purchased ~18,000 shares in early March at $13.83, a trade worth just under $250,000 and notable mainly because the rest of the insider register sold modest amounts around the same time. Net insider activity over the past 90 days is a small positive — roughly 33,000 shares net bought — but the dollar amounts are modest and most of the selling looks routine.
With the call on the tape today, the tension is whether a management able to defend the H2 EBITDA target can arrest the pattern of post-earnings drawdowns — and whether the short covering of the past week reflected that confidence, or simply pre-earnings risk reduction that could easily reverse.
See the live data behind this article on ORTEX.
Open FMC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
